指南与共识技术与安全MR

磁共振成像所用钆剂的滞留:批判性综述与监管机构建议

Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies.
指南 / 共识 · Radiologia · 2017-10-27

西班牙药品与健康产品管理局(AEMPS)基于欧洲药物警戒风险评估委员会建议,于2017年3月13日决定线性钆对比剂临床获益不抵风险并建议暂停其常规上市,同时保留Primovist和MultiHance用于肝脏研究及Magnevist关节腔内给药,并支持几乎专用大环类对比剂。本文作者不认同该建议,认为其未考虑各对比剂个体滞留差异,并呼吁开展前瞻性研究。

要点

  • AEMPS于2017年3月13日建议暂停线性钆剂常规上市,理由为脑内滞留。
  • AEMPS保留Primovist和MultiHance用于肝脏研究,并支持几乎专用大环类对比剂。
  • 作者不认同该建议,认为其未考虑各对比剂个体滞留差异。

核心结论

  • 作者不认同AEMPS最新建议中不考虑个体滞留特征即暂停线性钆剂上市的做法,认为该建议未基于现有滞留、弛豫率与临床效能数据。
  • 作者认为,既然安全性主要与组织间质滞留空间相关,目前似乎没有理由排除无肾源性系统性纤维化(NSF)相关病例的对比剂。
  • 作者提出有必要开展前瞻性研究,探讨这些有机钆沉积的组织学与临床相关性。

研究设计与样本

  • 本文为批判性综述,汇总监管机构建议与对比剂滞留相关证据,未报告系统检索范围与纳入文献数量。
  • 原文述及AEMPS于2017年3月13日基于欧洲药物警戒风险评估委员会建议作出决定。

诊断标准与关键数值

  • AEMPS于2017年3月13日认定线性钆对比剂(MultiHance、Omniscan、Magnevist〔目前未上市〕、Optimark〔西班牙已不再上市〕)临床获益不抵使用相关潜在风险。
  • AEMPS建议暂停上述线性钆对比剂常规上市,理由为其在脑内滞留。
  • AEMPS保留Primovist和MultiHance用于肝脏研究,并保留Magnevist用于关节腔内给药(西班牙未商业化)。
  • AEMPS支持几乎专用大环结构对比剂(Gadovist、ProHance、Dotarem)。

临床应用与阅片要点

  • 原文指出所有现有钆对比剂均有组织滞留的分布相,源于在骨、皮肤、肾、脑及其他器官间质中极缓慢交换。
  • 原文指出尚未证实与这些痕量钆蓄积相关的组织学效应或临床症状。
  • 原文指出这些对比剂的主要毒理学担忧与肾源性系统性纤维化(NSF)相关。

局限性

  • 原文为批判性综述,未报告系统检索范围与纳入文献数量。
  • 原文指出尚未证实与痕量钆蓄积相关的组织学效应或临床症状。
  • 原文提出有必要开展前瞻性研究,探讨有机钆沉积的组织学与临床相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The Spanish Agency for Drugs and Healthcare Products (AEMPS), based on the recommendations of the European Committee for Risk Assessment in Pharmacovigilance, established on 13 March 2017 that linear gadolinium-based MR contrast media, such as MultiHance, Omniscan, Magnevist (currently not marketed) and Optimark (no longer marketed in Spain), the clinical benefits do not outweigh the potential risks derived from their use. AEMPS recommends to suspend its marketing for general use based on the retention of these compounds in the brain. On the other hand, the AEMPS justifies the maintenance of Primovist and MultiHance for liver studies, and Magnevist of intra-articular administration (not commercialized in Spain), and justified the almost exclusive use of macrocyclic structure contrasts (Gadovist, ProHance and Dotarem). However, this retention is known to be different for each of the contrast media. All existing gadolinium contrasts agents have a distribution phase with tissue retention, due to a very slow exchange, in the interstitium of bone, skin, kidney, brain and other organs. The existence of histological effects or clinical symptoms associated with the accumulation of these trace amounts of gadolinium has not been demonstrated. The major toxicological concern with these contrast agents is related to nephrogenic systemic fibrosis (NSF). Since the safety profiles are mainly related to the interstitial retention space in the tissues, it does not seem justified to actually exclude contrast media that do not have cases related to the NSF. Based on all of this, we disagree with the latest AEMPS recommendation suggesting the marketing stoppage of linear agents without considering the individual retention profiles. This recommendation is not based neither on the data nor existing knowledge about the retention, relaxivity and clinical efficiency of the Gd compounds. It is therefore necessary to carry out prospective studies on the histological and clinical relevance of these organic Gd deposits.

来源:Radiologia,查看原文。版权归原作者所有。

引用

  1. Martí-Bonmatí L, Martí-Bonmatí E. Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies. Radiologia. 2017. PMID: 29110904. doi:10.1016/j.rx.2017.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。